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Objectives Rheumatoid arthritis (RA) is a chronic inflammatory condition with increased all-
cause and cardiovascular mortality. Accumulating evidence indicates that the immune and 
autonomic nervous systems (ANS) are major contributors to the pathogenesis of 
cardiovascular disease. We performed the first systematic literature review to determine the 
prevalence and nature of ANS dysfunction in RA and whether there is a causal relationship 
between inflammation and ANS function.  
Methods Electronic databases (Medline, Central and Cochrane Library) were searched for 
studies of RA patients where autonomic function was assessed.  
Results Forty studies in total were included. ANS function was assessed by clinical 
cardiovascular reflex tests (CCTs)(n=18), heart rate variability (HRV)(n=15), catecholamines 
(n=5), biomarkers of sympathetic activity (n=5), sympathetic skin responses (n=5), cardiac 
baroreflex sensitivity (cBRS) (n=2) and pupillary light reflexes (n=2). 9 small studies 
reported a ~60% (median, range 20-86%) prevalence of ANS dysfunction (defined by 
abnormal CCTs) in RA. 73% of studies (n=27/37) reported at least one abnormality in ANS 
function: parasympathetic dysfunction (n=20/26, 77%), sympathetic dysfunction (n=16/30, 
53%) or reduced cBRS (n=1/2, 50%). An association between increased inflammation and 
ANS dysfunction was found (n=7/19, 37%) although causal relationships could not be 
elucidated from the studies available to date.   
Conclusions ANS dysfunction is prevalent in ~60% of RA patients. The main pattern of 
dysfunction is impairment of cardiovascular reflexes and altered HRV indicative of reduced 
cardiac parasympathetic (strong evidence) and elevated cardiac sympathetic activity (limited 
evidence). The literature to date is underpowered to determine causal relationships between 




 Rheumatoid arthritis (RA) is a chronic inflammatory condition predominantly 
affecting the synovial joints but leading to extra-articular manifestations. The increased 
cardiovascular mortality in RA patients (by up to 50%)(1-4) is not fully explained by the 
presence of traditional risk factors and remains an important research focus.(3, 5-13)  
The autonomic nervous system (ANS) plays a critical role in the normal regulation of 
cardiovascular disease through its effects on the heart, peripheral vasculature and kidneys 
(Fig. 1).(14) The ANS is broadly comprised of the sympathetic and parasympathetic branches 
which work independently or in counter-balance to ensure homeostasis is maintained. 
Accumulating evidence indicates that altered ANS function contributes to the pathogenesis of 
cardiovascular disease (15, 16) and is an important predictor of cardiovascular mortality.(14, 
17-19)  Indeed, recent animal studies have demonstrated mechanistic and reciprocating links 
between inflammation and ANS dysfunction.(20-26) Elevations in circulating pro-
inflammatory cytokines increase sympathetic activity (20, 21), reduce cardiovagal baroreflex 
sensitivity (22) and reduce heart rate variability (HRV) derived indices of cardiac 
parasympathetic activity (Fig. 1) (26); these are all features of ANS dysfunction associated 
with cardiovascular disease and increased mortality in humans.(14, 17-19) Therefore, 
determining ANS function in RA may provide prognostic benefit as well as improve 
understanding of underlying pathological mechanisms, and hence new improved therapeutic 
strategies. 
Assessing ANS function – an overview 
There are various clinical and research techniques that can be used to assess ANS 
function (Table 1); each with their relative merits and limitations.(27-43) 
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Clinical cardiovascular reflex tests (e.g. heart rate or blood pressure responses to 
orthostasis) allow for simple, quick and non-invasive detection of autonomic dysfunction 
with the additional benefit of grading severity.(28) These reflex tests however are unable to 
diagnose the cause of autonomic dysfunction, and hence should be interpreted within the 
clinical context.  
HRV is a useful, non-invasive research tool that provides an indirect assessment of 
cardiac ANS function.(35) Cyclical fluctuations in resting heart rate are caused by cardiac 
parasympathetic and sympathetic influences and modulated by baroreflex mechanisms. 
Statistically derived indices of HRV can indicate the contribution of these parasympathetic 
and sympathetic influences (38, 44), although the physiological interpretation of HRV 
metrics is an issue of debate.(45) Despite guidelines for HRV assessment and interpretation 
(Task Force of the European Society and the North American Society of Pacing and 
Electrophysiology 1996) there is variability in methodology and a lack of normative data;(35) 
which needs to be considered when comparing results between studies.  
Plasma or urinary catecholamines provide an estimate of global sympathetic activity 
but cannot delineate regional variations in sympathetic activity. Measured levels of 
catecholamines reflect metabolism and clearance, as well as resting sympathetic tone or 
release and are affected by numerous confounding factors (including medications, diurnal 
variation and concomitant diseases) that can make interpretation difficult.(37, 38) Other 
blood biomarkers of sympathetic activity (e.g. neuropeptide Y) have similar limitations.(30, 
41) Norepinephrine spillover studies, unlike plasma or urinary measurement, can assess 
organ-specific sympathetic activity but are invasive, expensive and technically 
challenging.(37, 38) Pharmacological agents (e.g. adrenoreceptor antagonists or 
sympathomimetics) interrogate the ANS system to characterise the precise mechanisms of 
ANS dysfunction but are invasive and carry inherent risk.(37)  
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Cardiovascular baroreflex sensitivity assesses cardiovascular control mechanisms that 
are important for beat-to-beat regulation of blood pressure. Baroreflex assessment involves 
simultaneous measurement of heart rate (HR) and blood pressure (BP) while subjects are 
resting quietly (e.g. spontaneous methods), and during perturbations of BP either by non-
invasive procedures (e.g. Valsalva’s manoeuvre, lower body negative pressure or neck 
suction pressure) or pharmacological agents (e.g. phenylephrine infusion).(27, 37) The 
relative strengths and weakness of the methods used for assessing baroreflex function have 
been reviewed elsewhere.(46) 
The microneurography technique uses tungsten microelectrodes to make intra-neural 
recordings (typically from the peroneal nerve) of sympathetic outflow to the muscle (blood 
vessel vasoconstrictor impulses) or skin.(37, 38) Muscle sympathetic nerve activity correlates 
well with cardiac sympathetic activity; is reproducible and well-tolerated in numerous disease 
populations; and allows quantification of resting activity and response to various stimuli. Its 
technically challenging nature is the main limitation of this procedure.(38)  
Cardiac sympathetic imaging is a minimally invasive research technique that allows 
for visualisation of various imaging agents (e.g. radio-labelled sympathomimetic amines) 
using single photon emission computed tomography.(37, 38) This technique has been used in 
cardiovascular disease and demonstrated prognostic significance; however its use is limited 
due to expense and lack of availability.(37) Other assessments such as pupillary light reflex 
responses(34) or sympathetic skin responses(32, 36) can provide an estimation of autonomic 
dysfunction; however their significance in cardiac autonomic function is not clear. 
In this article, we performed the first systematic literature review on ANS function in 
RA to: i) investigate whether there is sufficient evidence to determine if patients with RA 
have altered ANS function; ii) determine the prevalence and nature of any autonomic 
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dysregulation in patients with RA; iii) elucidate whether there is a causal relationship 
between systemic inflammation (e.g. clinical markers of disease activity, elevated 




Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines,(47) electronic databases (Medline, Central and Cochrane Library) 
were searched to identify articles between January 1974 and June 2013, in English. The 
search term “rheumatoid arthritis” was used in combination with each of the following terms 
(incorporating common assessments of ANS function, Table 1): “autonomic”, “sympathetic”, 
“parasympathetic”, “vagal”, “heart rate variability”, “baroreflex”, “catecholamine”, 
“epinephrine”, “norepinephrine”, “adrenaline”, “acetylcholine”, “noradrenaline”, 
“cardiovascular battery”, “Ewing”, “Valsalva”, “hand grip”,  “cold pressor”, “orthostasis” 
and “tilt”. 
6350 citations were identified and the summaries and/or abstracts were screened for 
relevance; clinical studies of adults with RA where at least one aspect of ANS function was 
assessed were deemed relevant. Following removal of duplicate and irrelevant articles 44 full 
articles were accessed. Irrelevant articles included those that were non-original research (e.g. 
review articles, editorials, letters etc.), non-RA and animal studies. The following eligibility 
criteria were applied: articles written in the English language; involving adults with RA; at 
least one known parameter of ANS function assessed and reported; and an attempt to assess 
the association between inflammation and ANS function either by inclusion of a non-RA 
control group, by statistical analysis within a cohort of RA patients, or by intervention with 
anti-inflammatory therapy. Four articles were excluded as they failed to meet the eligibility 
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criteria (association between inflammation and ANS function not assessed and did not 
include a non-RA control group). In total 40 articles were included in the review (Fig. 2). 
Data extraction was performed by one of the authors (A.M.A.). A quality assessment 
was made for each study by adapting a known quality assessment tool (see Appendix 1).(48) 
The following indices were assessed: study design, inclusion/exclusion criteria, disease 
characteristics, standardised testing conditions (e.g. time of test, subject position), 
standardised methodology for autonomic assessment (e.g. adhering to published guidelines), 
quality of autonomic assessment tool (e.g. more than one technique used), appropriate sample 
size (e.g. use of power calculations to determine sample size), appropriate statistical tests 
(e.g. adjustment made for group differences), and associations between ANS function and 
inflammation tested. Each index was graded between 0-2, and the total points added to give a 
final score between 0-18. A percentage was calculated to give a Quality Index Score (QIS). 
The quality assessment was performed by two authors (A.M.A. and J.P.F.) and disagreements 
were discussed until a consensus was reached. Each study was placed into one (or more) 
category representing parasympathetic function, sympathetic function and cardiac baroreflex 
sensitivity and scored as either normal or abnormal. At least one abnormal parameter of 
autonomic function was required to qualify as an abnormal study (i.e. no studies could be 
classified as both normal and abnormal in a single domain). Furthermore each study was 
classified according to the type of autonomic function test performed and placed into one 
category if comparisons were made between rheumatoid arthritis patients and controls: RA 
worse than control, no difference or RA better than control. Due to the large heterogeneity in 
the patient characteristics, tools of ANS assessment employed and parameters reported, no 





Forty articles were included in the review.(49-88) Thirty-six studies were case-
control, cross-sectional, observational (Table 2A), of which 3 had an interventional arm 
(Table 2B); 3 were cohort studies, of which 1 was cross-sectional; and 1 study utilized a 
randomized, placebo-controlled, single-blind, cross-over design (Table 2B). 
In all but six studies the diagnosis of RA was based on the 1987 revised criteria of the 
American Rheumatism Association.(89) Approximately 80% of patients studied were female 
with a mean age of ~50 years (estimated calculation from reported values). Mean reported 
disease duration (from 26 studies) was ~9 years; 4 studies included RA patients diagnosed <2 
years. Twenty three (of forty) studies reported RA medications which included disease 
modified anti-rheumatic drugs of which methotrexate was the most common. Other 
medications and co-morbidities were only reported in a few studies; but most studies (30 of 
40) excluded patients with conditions or medications affecting the ANS (e.g., diabetes 
mellitus, neurological disease, hypertension, heart failure, vaso-active drugs). 
 
Assessment of ANS Function 
 Eighteen studies utilized clinical cardiovascular tests (CCTs) of ANS function;(51, 
53, 54, 58, 60, 62, 69, 74-83, 85) 15 studies assessed heart rate variability (HRV)(49-51, 55, 
57, 59, 61, 65, 68, 71, 73, 77, 86-88) of which 5 assessed HRV in combination with clinical 
cardiovascular reactivity;(51, 68, 77, 86, 87) and 16 studies used other methods of assessing 
ANS function including catecholamines (n=5),(66, 67, 84, 86, 87) biomarkers (n=5),(56, 63, 
64, 86, 87) sympathetic skin responses (SSR)(n=5),(60, 62, 69, 70, 82) cardiac baroreflex 
sensitivity (cBRS)(n=2)(50, 51) and pupillary light reflexes (PLR)(n=2).(52, 80) Studies 
assessed either one (n=30), two (n=8) or three (n=2) parameters of ANS function. 
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Assessments of ANS function undertaken in RA patients can be broadly categorised 
into: parasympathetic activity;(27) sympathetic activity;(38) and cBRS.(37) Resting activity 
was assessed in addition to the response to stimuli. For the purposes of this review ANS 
dysfunction is defined as either: abnormality in CCTs; impaired HRV and/or disrupted 
sympatho-vagal balance; reduced cBRS; altered concentrations of catecholamines or 
biomarkers of sympathetic activity; impairment in SSR; impairment in PLR; abnormalities in 
the above parameters occurring either at rest or following various stimuli. 
 
Prevalence of ANS dysfunction 
 73% of studies (n=27/37) reported at least one abnormality in ANS function in RA 
patients. Nine studies reported the prevalence of ANS dysfunction, determined from 
abnormal CCTs, in RA patients with varying results (median prevalence 60%, range 33-86%) 
(see Appendix 2).(51, 54, 58, 60, 62, 77, 80, 81, 83). The wide range in prevalence is 
reflective of variations in criteria for ANS dysfunction; numbers of patients included in 
studies (n=10-50); and assessments of ANS function performed. CCTs, unlike many others 
assessments of ANS function have validated reference values and established criteria for 




 Parasympathetic activity in RA patients was assessed by 25 case-control, cross-
sectional observational studies and 1 cohort study using: CCTs (n=14) with HR responses to 
deep breathing(51, 53, 58, 62, 74-83) and/or orthostasis(51, 53, 58, 74-81, 83) and/or 
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Valsalva’s manoeuvre)(51, 53, 58, 76, 78-81, 83); HRV (n=13) with time domain(49, 59, 61, 
68, 71, 77, 88) and/or frequency domain parameters,(51, 55, 59, 61, 68, 86-88) respiratory 
sinus arrhythmia (RSA)(57) or heart rate turbulence (HRT)(50); and the PLR (n=2)(52, 80) 
with constriction and/or maximum velocity latency (Table 2). 
 Of the 26 cross-sectional studies assessing parasympathetic activity, approximately 
77% reported parasympathetic dysfunction (Table 3). The main pattern of parasympathetic 
dysfunction included impaired clinical cardiovascular reflexes (85%) and abnormal HRV 
indices (62%)(Table 4). When studies of low quality were excluded (QIS less than 50%) 
most studies using CCTs found parasympathetic dysfunction (7 of 8) which was supported by 
abnormal HRV in most studies (7 of 12). Most of the studies that failed to demonstrate an 
abnormality in parasympathetic function assessed females only (n=5/7) who were relatively 
young (mean age range 31-56 years); a demographic known to have elevated HRV indices of 
parasympathetic activity possibly reflecting the effects of oestrogen.(90-93) 
 For example, Piha et al(78) found a higher resting HR in 43 female RA patients (mean 
age 49 years) compared to 69 female controls (mean age 43 years) which may suggest 
reduced resting parasympathetic activity in the RA group. They reported impaired HR 
(parasympathetic) responses to orthostasis and Valsalva’s manoeuvre in RA patients, which 
was statistically non-significant when age and resting HR were used as co-variates. Although 
elevations in resting HR may be a result of autonomic dysfunction other factors are known to 
contribute (e.g. anaemia, infection, anxiety, medications). 
 Avsar et al(50) reported no difference in HRT in 26 RA patients (18 females, mean 
age 56 years) compared to 26 well matched healthy controls. HRT assesses the autonomic 
response to ventricular premature complexes (VPC) (Table 1) and hence there is a selection 
bias inherent to this technique; the ANS function of subjects without VPCs cannot be 
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assessed. Secondly, no power calculation was reported and larger studies (>100 patients) 
were required to predict cardiovascular risk using HRT.(40) 
 
Sympathetic dysfunction  
Sympathetic activity in RA patients was assessed by 29 case-control, cross-sectional 
observational studies and 1 cohort study using CCTs (n=13) with BP responses to 
orthostasis(51, 53, 54, 74-77, 79-81) and/or handgrip(51, 54, 79, 81) and/or cold pressor 
tests(54) and/or mental stress(60, 69, 85); HRV (n=10) with frequency domain 
parameters,(51, 55, 59, 61, 68, 77, 86-88) pre-ejection period (PEP)(57); biomarkers of 
sympathetic activity (n=5) with plasma neuropeptide Y (NPY)(63, 64, 72, 86), serum 
chromogranin(56); SSR (n=5)(60, 62, 69, 70, 82); catecholamines (n=4) with plasma(67, 86, 
87) or urinary(66) epinephrine (EPI), norepinephrine (NE); PLR (n=1) with maximal area in 
darkness.(80) 
 Of the 30 studies assessing sympathetic activity over half reported sympathetic 
dysfunction (Table 3). The main pattern of sympathetic dysfunction included impaired 
clinical cardiovascular reflexes (67%), whilst HRV parameters of sympathetic activity were 
normal in the majority of studies (70%)(Table 4). When studies of low quality were excluded 
(QIS less than 50%) most studies using CCTs found sympathetic dysfunction (6 of 9) 
however this was not supported by abnormal HRV in the majority of studies (2 of 10). 
 The majority of studies that failed to demonstrate sympathetic dysfunction in RA 
patients were of predominantly pre-menopausal women, which as discussed previously may 
cause confounding results. Other possible explanations for negative findings include: failure 
to control for medications that are known to have an effect on the ANS(85); underpowered 
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studies(63, 75); selection bias when matching controls to RA patients(75); and limitations 
inherent to ANS assessments for example lack of standardised testing conditions (see 
introduction).  
Baroreflex sensitivity 
Of the two cross-sectional, case-control, observational studies(50, 51) assessing cBRS 
one reported abnormality in RA compared to controls (Tables 3, 4).(51) Aydemir et al(51) 
reported a lower resting cBRS (using the sequence technique) in 36 RA patients (30 females, 
mean age 49 years) compared to 40 age and gender matched controls.(51) Avsar et al found 
no difference in HRT in 26 RA patients (mean age 56±10 years, 18 female) and 26 age and 
sex matched healthy controls (mean age 55 years, 18 females).(50) 
 
Time course of ANS dysfunction 
Three studies assessed patients with early RA (duration<2years); (57, 60, 63) and in 2 
studies sympathetic dysfunction was reported (increased resting sympathetic activity and 
impaired sympathetic responses to mental stress).(57, 60) These few studies suggest that 
ANS dysfunction in RA may not necessarily be a consequence of long-term disease and 
inflammatory burden. 
 Dekkers et al(57) found no difference in respiratory sinus arrhythmia (RSA), a marker 
of parasympathetic activity in 25 RA patients (19 females, mean age 55 years) compared to 
well matched healthy controls. RA patients included in this study had a low erythrocyte 
sedimentation rate (ESR, mean 15 mm/1st hour) and a disease duration <2 years, suggesting 
that parasympathetic dysfunction may be a late phenomenon. They also reported increased 
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sympathetic activity (PEP) in RA patients compared to controls suggesting that sympathetic 
dysfunction may precede parasympathetic dysfunction.  
 
Inflammation and ANS dysfunction 
Observational studies 
 Twenty four studies reported at least one marker of disease severity including ESR 
(n=19; range 14-61 mm/1st hour)(49, 51, 53, 57, 59, 60, 63, 66, 67, 71, 73, 75, 77, 78, 80-82, 
84, 85), CRP (n=12; 5-380 mg/L)(51, 53, 59, 61, 67, 68, 71, 73, 80, 82, 85, 87) and disease 
activity score (DAS or DAS28; a clinical index comprising of number of swollen and tender 
joints, acute phase response typically CRP or ESR, and general health)(94)(n=8; 6 moderate 
and 2 severe)(49, 51, 55, 61, 65, 68, 85, 87). ANS dysfunction was reported more frequently 
in those studies with higher CRP values (5 v 2; CRP≥14.5 v <14.5 mg/L) and mainly 
comprised of parasympathetic dysfunction: reduced HRV indices of cardiac parasympathetic 
control (n=3)(59, 61, 71); and impaired heart rate responses to deep breathing, orthostasis and 
Valsalva’s manoeuvre (n=1)(80).  
 Approximately one third of studies (n=7/19) reported an association between ANS 
function and inflammation: CCTs (n=2/9); HRV (n=3/5); biomarkers of sympathetic activity 
(n=1/2); and PLR (n=1/1) (Table 5). When low quality studies were excluded (QIS less than 
50%) only 5 of 14 studies found an association. 
In 7 more recent studies (≥1993) using CCTs,(51, 60, 75, 78, 79, 81, 83) no 
significant correlation was found in RA patients between ANS function and any of the 
following: ESR, CRP, the Ritchie articular index (assessment of joint tenderness and 
swelling), the presence of an inflammatory syndrome (not defined), DAS28 (an updated 
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version of DAS with clinical assessment of 28 joints), disease duration, presence of 
rheumatoid factor or articular damage on radiograph. 
Yadav et al(88) studied 45 RA patients (41 females, mean age 41 years) and found a 
significant positive correlation between DAS28 and a parasympathetic index of HRV. 
Anichkov et al(49) also found a correlation between 24-hour HRV parameters of 
parasympathetic function and markers of disease severity and inflammation such as number 
of swollen joints, Ritchie articular index, disease activity score  and leucocyte count. Dekkers 
et al(57) (described earlier in review) reported that higher sympathetic activity (determined 
from PEP) was associated with higher disease activity (ESR and Thompson joint score). 
Two studies found no significant correlation between catecholamines and 
inflammatory indices. Vlcek et al(87) found no significant correlation between plasma 
catecholamines and inflammation (CRP, DAS28-CRP). Van Middendorp et al(84) found no 
correlation between 24 hour urinary noradrenaline excretion and markers of inflammation 
(ESR or interleukin-6) in a cohort of 60 RA patients (38 females, mean age 59 years). Igari et 
al(66) in a sub-study of 6 RA patients who underwent synovectomy found that 24 hour 
urinary adrenaline and noradrenaline significantly decreased 2 weeks following 
synovectomy. Although the investigators did not assess inflammatory markers following 
synovectomy, it may be assumed that local joint inflammation would have been reduced 
following synovectomy and hence possibly removing the stimulus for sympathetic activation. 
Barendregt et al(52) found that ESR levels were higher in the group with 
parasympathetic dysfunction (abnormal PLR in the RA group with ocular dryness) compared 





Two studies investigated HRV in RA patients receiving tumour necrosis factor (TNF) 
alpha inhibitor therapy.(65, 73) Holman et al(65) studied 33 patients (25 with RA, 8 with 
psoriatic arthritis) before treatment with TNF-alpha inhibitor therapy and assessed clinical 
response to treatment (using American College of Rheumatology criteria ACR20/50/70 and 
DAS28) at various time points up to one year. They found that low HRV indices, reduced 
parasympathetic and increased sympathetic activity were predictors of poor response to TNF-
alpha inhibitor therapy. However the study may have been underpowered as they found no 
direct correlation between baseline autonomic function and change in DAS28 score following 
TNF-alpha inhibitor therapy. Despite limitations of the study (one third of patients 
discontinued therapy by one year; use and dosage of other medications were not controlled; 
small numbers of RA patients) these results suggest that HRV and sympatho-parasympathetic 
balance may play an important role in disease activity. 
Two studies assessed plasma NPY levels before and after TNF-alpha inhibitor 
therapy. In a study of 16 female RA patients Kopec-Medrek et al(72) found that infliximab 
(TNF-alpha inhibitor) significantly reduced inflammation (CRP, ESR) but did not reduce 
sympathetic activity (plasma NPY). In fact, plasma NPY concentrations rose to a peak after 6 
infusions of infliximab and fell to baseline levels 8 weeks after the ninth (final) infusion. The 
authors did however report a positive correlation between plasma NPY concentrations and 
CRP (Kendall tau coefficient=0.506, P<0.006) and DAS28 (Kendall tau coefficient=0.393, 
P<0.033) at baseline, indicating that plasma NPY may reflect inflammatory status.  
Harle et al (64) found that in a cohort of RA patients, adalimumab (TNF-alpha 
inhibitor) had no effect on serum NPY levels despite good clinical response. They reported 
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higher plasma NPY concentrations in RA patients with previous prednisolone use only, 
indicating a possible interaction effect with the hypothalamic-pituitary-adrenal axis. 
 
DISCUSSION 
The results of this systematic literature review indicate that ANS dysfunction is 
prevalent in ~60% (33-86%) of RA patients as determined from observational studies of 
small sample size (10-50 patients). Stronger evidence (from large prospective cohort studies) 
is required to confidently determine the true prevalence of autonomic dysfunction in RA. 
HRV is probably the most feasible ANS assessment in such a large population. Few studies 
have assessed patients with early RA (duration<2years) but have shown that ANS 
dysfunction occurs early in RA and is not necessarily an effect of long-term disease and 
inflammatory burden. More studies of RA patients with early disease are clearly needed and 
if possible ANS assessment preceding the onset of RA, to determine whether altered ANS 
function predisposes to developing RA. 
Studies using CCTs in RA have shown reduced resting parasympathetic activity and 
impairment in both sympathetic and parasympathetic reflex responses. Strong evidence from 
good quality HRV data supports these findings with the majority demonstrating low HRV 
reflecting reduced resting parasympathetic activity. In addition there is limited evidence for 
elevated resting sympathetic activity with the majority of good quality HRV data failing to 
detect abnormal sympathetic function in RA. Studies employing other methods of ANS 
assessment have shown conflicting results, which may reflect their inherent limitations. There 
is a lack of evidence from the literature to date to determine causal relationships between 
systemic inflammation and autonomic dysfunction. The available literature is too small to be 
clear whether the lack of evidence represents a lack of relationship or simply inadequate 
power. Only two studies assessed the effects of anti-inflammatory therapy on ANS function 
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and failed to demonstrate an effect. However, their results suggest that plasma NPY may not 
be a reliable method of assessing sympathetic activity particularly as the effects of steroids on 
NPY are not known. Further interventional studies are needed to elucidate causation. The 
most feasible and ethical study design would be to assess ANS function in RA patients prior 
to and after anti-inflammatory therapy. This could be achieved for example with HRV 
assessments using a 24-hour electrocardiograph holter. Although HRV is not routinely used 
in clinical practice one study suggested a possible clinical role. Holman et al (65) found that 
low HRV in RA patients predicted a poor response to TNF-alpha inhibitor therapy indicating 
a possible benefit in determining ANS status prior to initiation of biologic agents. What 
remains unknown however is whether therapy to improve HRV in these patients would 
improve their response to anti-inflammatory agents. 
Less than half the studies demonstrated an association between increased 
inflammation and ANS dysfunction (mainly CCTs and HRV), consistent with the results of 
recent animal studies.(20-22) The lack of associations in the remaining studies may be simply 
due to a lack of statistical power; the majority of studies in our review did not report a power 
calculation. Another possible explanation may be the relatively low inflammatory status of 
patients tested. CRP, ESR and DAS (reported in less than two thirds of studies) were only 
modestly elevated although it is unclear whether cumulative inflammatory burden can be 
determined from assessment at a single time point.. Another explanation for a lack of 
association between inflammation and ANS function in the studies included in our review 
may be the subtle nature of autonomic dysfunction present in RA or simply the inappropriate 
choice of immune markers assessed.    
The main limitations of this review are the types and number of ANS tests employed 
in RA patients, with the majority of studies making only one assessment of ANS function. 
ANS function is complex and multi-faceted and hence a comprehensive assessment is 
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required in order to fully categorise the presence of dysfunction. Future studies should 
include a greater variety of tests including arterial baroreflex assessment, with attempts to 
measure resting ANS function and response to stimuli. Larger sample sizes are required to 
confirm the prevalence of ANS in RA, and in order to ensure that statistical power is 
achieved.  
Future studies in RA should aim to characterise the inflammatory profile of patients 
studied so that causal links between inflammation and ANS dysfunction can be determined. 
The effects of RA medications on ANS function is not fully known and is a difficult 
confounding factor to control for, especially as RA patients often require medications to 
induce and maintain remission of disease. One study showed that infliximab infusion (TNF-
alpha inhibitor therapy) caused an acute reduction in HRV and sympathetic activity compared 
to a placebo. The effects of other RA medications on the ANS tests employed to date are 
unknown although studies of healthy subjects may be the most ethically acceptable way to 
investigate this. 
Another difficulty is discerning between the effects of RA and concomitant co-
morbidities or medications on ANS function. Although many studies excluded RA patients 
with conditions or medications affecting the ANS system, cardiovascular disease (CVD) 
remains under-diagnosed in this population.(6, 8, 11) Cardiac imaging (e.g. echocardiography 
or magnetic resonance imaging) to identify such patients and the possible inclusion of a 
cardiovascular disease control group may help tackle this problem. 
 In conclusion, the evidence to date supports that ANS dysfunction is a feature of RA 
although not universally found in all patients. The profile of ANS dysfunction found in RA 
patients (low HRV, reduced parasympathetic activity and elevated sympathetic activity) is 
associated with increased cardiovascular and mortality risk and may help to explain the 
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increased risk in RA patients. Furthermore, this pattern of ANS dysfunction supports the 
findings from animal studies and may be a consequence of high inflammatory burden. 
Although associations between inflammation and ANS dysfunction are present in RA 
patients, the available literature is too small and underpowered to be clear about causality. 
Further studies are required to: determine the true prevalence of ANS dysfunction in RA, 
characterise RA patients who have altered ANS function; determine the prognostic role of 
ANS assessments in predicting cardiovascular and mortality risk; assess the effects of 
biologic agents on ANS function; consider the role of therapeutic strategies targeting the 
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Table 1. Definition of ANS assessments included in the review 
 






Heart rate response to 
orthostasis(28) 
Heart rate response to standing up 
unaided following a period of lying 
quietly on a couch. Normal response is an 
immediate increase in heart rate (around 
the 15th beat) after standing followed by a 
nadir in heart rate (around the 30th beat). 
The 30:15 ratio (of the longest inter-beat 
(RR) interval around the 30th beat to the 
shortest RR-interval around the 15th beat) 
forms part of the Ewing battery of 
cardiovascular tests. 




Heart rate response to 
Valsalva’s 
manoeuvre(28) 
Heart rate response to straining against a 
closed glottis at a pressure of 40mmHg 
for 15 seconds. The Valsalva ratio (of the 
longest RR- interval shortly after the 
manoeuvre followed by a rebound 
bradycardia after release) forms part of 
the Ewing’s battery of cardiovascular 







Heart rate variation to 
deep breathing(28) 
Heart rate (HR) variation to deep 
breathing at a rate of 6 breaths per 
minute. The mean differences between 
the maximum and minimum heart rates 
during each breathing cycle forms part of 
the Ewing’s battery of cardiovascular 
tests. 




Strengths: Simple, bedside tests; non-invasive; inexpensive; normative values available; 
allows grading of severity when tests used in combination.(28) 
Weaknesses: Indirect measures of parasympathetic activity; some parameters also influenced 
by sympathetic and baroreflex activity (e.g. Valsalva’s manoeuvre)(27); relies on experienced 
practitioners; multiple factors can affect responses to Valsalva’s maneouvre (volume and rate 
of pre-strain breath, strain pressure, depth and duration, standing v supine) and deep 
breathing (rate and depth of breathing)(37); provides limited information about the 
mechanism of autonomic dysfunction; single tests are not reliable in detecting autonomic 
dysfunction as there is a poor correlation between the various indices.(37) 




rMSSD(35) Square root of the mean of the sum of the 
squares of difference between adjacent 
inter-beat (NN) intervals. Time domain 
estimate of short-term components of 
HRV. 
Reduced levels 
indicate low heart 
rate variability and 
parasympathetic 
dysfunction 
NN50(35) Number of pairs of adjacent NN intervals 
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differing by more than 50 milliseconds in 
the entire recording. Time domain 
measure. 
pNN50%(35) NN50 as a percentage of the total number 
of all NN intervals. Time domain 
measure. 
SDNN(35) Standard deviation of all NN intervals. 
Estimate of overall HRV. Time domain 
measure. 
SDANN(35) Standard deviation of the averages of NN 
intervals in all 5 minute segments of the 
entire recording. Time domain estimate 
of long-term components of HRV. 
SDSD(35) Standard deviation of differences 
between adjacent NN intervals. Time 
domain measure. 
HF power(35) High frequency power of pulse interval in 






SD1(39) Standard deviation of the Poincare plot 




heart rate variability 
Strengths: Non-invasive; inexpensive; reproducible; automated analysis; resting activity and 
responses to stimuli can be measured; Task Force guidelines(35) exist for the optimum utility 
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of this technique; 24 hour holter monitoring provides a measure of autonomic function in 
“real life” environment therefore a good clinical technique to monitor responses to 
interventions. 
Weaknesses: Indirect measure of autonomic activity; no normative values exist; despite the 
availability of guidelines the variability in methodology makes it difficult to compare values 
between studies. 
Heart rate turbulence 
(HRT) – turbulence 
onset(40) 
Early acceleration of the heart rate 
immediately following a ventricular 






Strengths: Non-invasive; inexpensive; automated analysis; 24 hour holter monitoring 
provides a measure of autonomic function in “real life” environment therefore a good clinical 
technique to monitor responses to interventions. 
Weaknesses: Indirect measure of autonomic activity; no normative values exist; relies on the 
presence of premature ventricular beats.(40) 
Respiratory sinus 
arrhythmia(31) 
Rhythmical fluctuations in heart rate 
periods during inspiration (rise) and 






Strengths: Non-invasive; inexpensive; selective index of vagal control of the heart.(31) 
Weaknesses: Results can be affected by rate and depth of breathing; provides a measure of 
resting autonomic activity only. 
Pupillary Light Reflex   
Constriction latency(34) Measure of the onset of pupillary 
constriction in response to light stimulus. 







Measure of the maximum constriction 
velocity in response to light stimulus. 




Strengths: Non-invasive; inexpensive; validated(34); normative values available; allows 
grading of severity. 
Weaknesses: Provides limited information about the mechanism of autonomic dysfunction; 







Systolic blood pressure 
response to 
orthostasis(28) 
Systolic blood pressure response to 
standing up unaided following a period of 
lying quietly on a couch. The postural 
drop in systolic blood pressure forms part 
of the Ewing’s battery of cardiovascular 
tests. 
Decrease in systolic 




Blood pressure response 
to sustained handgrip(28) 
Blood pressure response to sustained 
handgrip (30% of the maximum 
voluntary contraction using a handgrip 
dynamometer for up to 5 minutes). The 
difference between diastolic blood 
pressure before starting and just prior to 
Increase in diastolic 






releasing handgrip forms part of the 
Ewing’s battery of cardiovascular tests. 
Blood pressure response 
to cold pressor test(37) 
Blood pressure response to immersion of 
hand in a container of ice water for 1-3 









Blood pressure response 
to mental stress(37) 
Blood pressure response to mental stress 
tasks (such as mental arithmetic or the 
Stroop colour-word naming test) which 
results in sympatho-excitation. 
Heart rate response to 
mental stress(37) 
Heart rate response to mental stress tasks 
(such as mental arithmetic or the Stroop 
colour-word naming test) which results in 
sympatho-excitation. 
Strengths: Non-invasive; inexpensive; normative values available for responses to 
orthostasis and handgrip(28); allows grading of severity.(28) 
Weaknesses: Relies on experienced practitioners; difficult to standardise muscle effort 
during sustained handgrip; wide variability in inter-subject responses to cold pressor test and 
mental stress; provides limited information about the mechanism of autonomic dysfunction; 
single tests are not reliable in detecting autonomic dysfunction(28); cold pressor, mental 
stress and handgrip responses have a low sensitivity and specificity for detecting sympathetic 
dysfunction.(37) 
Heart Rate Variability   
LF power(35) Low frequency power of pulse interval in 





domain measure indicating mainly 
sympathetic activity (but also small 
parasympathetic component). 
sympathetic activity 
LF/HF ratio(35) Ratio of low frequency / high frequency 
power of pulse intervals. Frequency 







Strengths: Non-invasive; cheap; reproducible; automated analysis; resting activity and 
responses to stimuli can be measured; Task Force guidelines(35) exist for the optimum utility 
of this technique; 24 hour holter monitoring provides a measure of autonomic function in 
“real life” environment therefore a good clinical technique to monitor responses to 
interventions. 
Weaknesses: Indirect measure of autonomic activity; no normative values exist; despite the 
availability of guidelines the variability in methodology makes it difficult to compare values 
between studies; LF power has contributions from the parasympathetic nervous system and 
hence not purely a measure of sympathetic activity.(46) 
Pre-ejection period 
(PEP)(29, 33) 
The interval from the onset of the Q wave 
(on an ECG) to the left ventricular 
ejection (detected using impedence 
cardiography). Pre-ejection period is 
inversely related to myocardial 
contractility and can represent 




Strengths: Non-invasive; provides a reliable measure of systolic time intervals; can provide a 
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measure of resting activity and response to stimuli.(33) 
Weaknesses: Indirect measure of cardiac autonomic influences; lack of standardised 
methodology; derived values of stroke volume and cardiac output are less reliable(29); pre-
ejection period may be confounded by changes in preload or afterload.(33) 
Microneurography 
Muscle sympathetic 
nerve activity(37, 38) 
Intra-neural recordings of muscle 
sympathetic nerve activity (MSNA) using 
tungsten microelectrodes inserted 
percutaneous into a peripheral nerve 
(typically peroneal nerve) allow direct 
measurement of vasoconstrictor 




Strengths: Direct and continuous measure of muscle sympathetic outflow; correlates with 
cardiac sympathetic activity; reproducible; well tolerated in healthy disease populations; can 
record for several hours at a time; allows quantification of resting activity as well as response 
to stimuli.(38) 
Weaknesses: Invasive; technically challenging procedure. 
Catecholamines or Biomarkers of Sympathetic Activity 
Catecholamines(37) Catecholamines such as epinephrine, 
norepinephrine and their metabolites 
detected in the plasma or urine (24 hour 
collection) may represent sympathetic 
activity. Confounding factors include 
medications, diurnal variations and 
concomitant diseases. 







Peripheral marker peptide released with 




Acidic, soluble proteins with widespread 
neuroendocrine distribution in secretory 
vesicles, co-released with catecholamines 
by exocytosis from vesicles in adrenal 
medulla and sympathetic nerve endings. 
Strengths: Minimally invasive; inexpensive; plasma levels allow measurement of resting 
activity and response to stimuli. 
Weaknesses: Difficult to measure; represents global sympathetic activity and cannot 
delineate regional variances; plasma levels of catecholamines reflect uptake, release and 
clearance whilst urinary levels are dependent on renal function; can be confounded by 
medications, diurnal variations and concomitant diseases.(38) 
Norepinephrine spillover 
(37, 38) 
Regional or organ-specific 
norepinephrine spillover measurements 






Strengths: Allows direct measurement of organ specific sympathetic activity. 
Weaknesses: Invasive; considerable costs; technically challenging.(38) 
Cardiac sympathetic 
imaging (37, 38) 
Imaging agents (e.g. radio-labelled 
sympathomimetic amines) can be 
detected using single photon emission 
computed tomography, providing visual 
representation of sympathetic activity. 
Provides images 
showing areas of  




Has been used to demonstrate cardiac 
sympathetic denervation in 
cardiovascular disease and has prognostic 
significance. 
Strengths: Allows direct measurement of organ specific sympathetic activity; provides 
structural and functional assessment of the sympathetic nervous system; can provide 
quantification of organ specific noradrenergic uptake.(38) 
Weaknesses: Minimally invasive; considerable costs; limited availability; assessing 
sympathetic activity in the heart can be technically difficult.(38) 
Other Assessments 
Pupillary light reflex 
maximal pupillary area in 
darkness(34) 
Measure of maximal pupillary area in 
response to darkness. 




Strengths: Non-invasive; inexpensive; validated; normative values available; allows grading 
of severity.(34) 
Weaknesses: Provides limited information about the mechanism of autonomic dysfunction; 
can be confounded by impairments in ocular muscle function and retinopathy.(34) 
Sympathetic skin 
responses(32, 36) 
Changes in skin electrical conductance in 
response to various stimuli (such as 






Strengths: Non-invasive; simple; fast; inexpensive.  
Weaknesses: Wide intra- and inter-subject variability in sympathetic skin responses due to 
confounding factors (e.g. ambient temperature, skin temperature, mental or emotional state, 
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habituation with repeated stimuli); low sensitivity and specificity; poor correlation with other 
autonomic assessments (e.g. sudomotor dysfunction).(36) 








Spontaneous assessment involving 
simultaneous recording of blood pressure 
and RR interval whilst the patient rests 
quietly. A computer is used to identify 
sequences of three or more consecutive 
beats characterised by a progressive 
increase or decrease in BP which results 
in lengthening or shortening of the RR 
interval (consecutively). Regression slope 
of SBP and RR interval provides a 





Strengths: Non-invasive; simple; inexpensive; automated analysis; reliable; provides distinct 
measurements for rising and falling blood pressures.(17, 43) 
Weaknesses: No normative values exist; relies on the presence of sequences; marked within 




Phenylephrine (vasoconstrictor) causes 
increase in blood pressure which results 




heart rate. Regression slope of SBP and 
RR interval or heart rate provides a 
measure of cardiac baroreflex sensitivity. 
Strengths: Inexpensive; usually produces a high correlation between blood pressure and RR 
interval suggesting it is a good indicator of arterial baroreflex gain.(37) 
Weaknesses: Invasive; no normative values exist; only assesses the response to rises in blood 
pressure which may be reduced in subjects with low resting sympathetic outflow (typically 
young healthy individuals).(37) 
Heart rate turbulence -  
turbulence slope(40, 95) 
Rate of late deceleration (after early 
acceleration) of the heart rate 
immediately following a ventricular 






Strengths: Non-invasive; inexpensive; automated analysis; 24 hour holter monitoring 
provides a measure of autonomic function in “real life” environment therefore a good clinical 
technique to monitor responses to interventions. 
Weaknesses: Indirect measure of autonomic activity; no normative values exist; relies on the 
presence of premature ventricular beats.(40) 
   
BP = blood pressure, ECG = electrocardiogram, HR = heart rate, HRV = heart rate 





Table 2. Characteristics of studies included in the review 
A. Cross-sectional, observational, case-control studies 
 
Study Year N Characteristics Inclusion 
Exclusion 
Assessment Key findings QIS 
Clinical cardiovascular tests (n=17) 





30 female, 49 years 
Disease duration 
11.2 years DAS28 
4.1 
CRP 11mg/L 
ESR 33 mm/1st 
hour 









DB, O, VM  
 
BP response 
to HG, O 
Abnormal 
cardiovascular 








Higher resting HR 

























to CP, HG, O 
Higher resting HR 





















32 female, 56 years 
25 RF positive 
ESR 14.3 mm/1st 
hour 
 
































33 female, 58 years 
Disease duration 
9.5years 
64% RF positive 
ESR 14.3 mm/1st 
hour 






















19 female, 52 years 
 
BP response 
to HG, O 
sympathetic and 
parasympathetic 



















CRP 10.4 mg/L  




I: ARA 1987 
criteria, able 


















mental stress seen 














39 female, median 
63 years 
Steinbrocker’s 
class 1 or 2 
76% RF positive 
None had evidence 
of current flare in 
joint 
7 had peripheral 
nerve damage 
 









DB, O, VM 
 
BP response 
to HG, O 
Abnormal 
cardiovascular 
tests in RA – 
worse in patients 
with peripheral 







response to HG) 

















10 females, 49 
years 






RR interval  
variation at 




















No females, 64 
years 








Higher resting HR 






















response to mental 


















15.5 swollen joints 
Ritchie articular 
index 11.6 
56% RF positive 
ESR 35.2 mm/1st 
hour 
 















tests in RA 
 
Parasympathetic 






(ESR, number of 
swollen joints) 




50 females, 47 
years 
34 age and gender 
match controls 















ESR 23.2 mm/1st 
hour 
 





















in response to 































in response to 



























ESR 23 mm/1st 
hour 
I: ARA 1987 
criteria 















tests in RA 
 
Impaired HR and 
BP (sympathetic) 











16 females, 53 
years 










class: I = 6, II = 20, 
III = 8 
28 had arthritis in 3 
or more joint areas 
and positive 
findings on hand 
radiographs 
ESR 23 mm/1st 
hour 









DB, O, VM 






responses to O and 
VM (which were 
statistically 
insignificant when 































function class: II = 
25, III = 5  
CRP 380 mg/L 
ESR 61 mm/1st 
hour 
 



































31 females, 56 
years 
Disease duration 6 
years 





to DB, O, VM 
Abnormal 
cardiovascular 























response to VM 































function class: II = 
6, III = 8, IV = 2.  
All had erosions 
 

























tests in RA 
patients with a 







response to DB 
and O) and 
sympathetic 
responses (BP 
response to O) 
found in RA 
patients with high 
disease severity 































responses in RA 
patients 
 
Mean ESR higher 
in RA patients 
























HRV tests (n=13) 




2012 RA  
45 





CRP 8.6 mg/L 





status = class 

















balance at rest 
and in response 
to O 
Higher resting 
HR in RA 
 





























CRP 7.5 mg/L 
 













balance at rest 
and in response 
to O 
Normal HRV at 
rest and in 











39 females, 41 
years 


















































24 hour holter 























30 females, 49 
years 
I: ARA 1987 
criteria 
E: Condition 


















balance at rest 












11 RF positive 
DAS28-CRP 3.9 
 


























32 females, 56 
years 
25 RF positive 
ESR 14.3 mm/1st 
hour 






































8 females, 31 
years 










at rest and in 
response to O 
Normal HRV at 
rest and in 

















23 females, 48 
years 
Disease duration 4 
years 
























































































6 females, median 
38 years 






8.4 years  
CRP 51.4 mg/L 
ESR 42.6 mm/1st 
hour 
 































ESR 15 mm/1st 
hour 































































35 RF positive 
Steinbrocker’s 
function class: I = 
16, II = 18, III = 8 
CRP 50.3 mg/L 
ESR 41.7 mm/1st 
hour 
 

































































































14 females, 58 
years 
 























8 females, 31 
years 






activity) at rest 


























9 tender joints 
7.5 swollen joints 
ESR 27.7 mm/1st 
hour. 





and tested in 
the early to 
mid-follicular 


































NPY higher in 
long-standing 





























Skin sympathetic responses (n=5) 





10 females, 49 
years 























No females, 64 
years 
I: RA (clinical 
diagnosis), 
male 
































VAS pain 26mm 
ESR 23 mm/1st 
hour 
 
I: ARA 1987 
criteria 































































function class: II = 
25, III = 5  
ESR 61 mm/1st 
hour 
CRP 380 mg/L 
 



















26 females, 50 yrs 
 
Catecholamines (n=4) 















CRP 7.5 mg/L 
 







Plasma EPI and 
NE (sympathetic 
activity) at rest 
and in response 
to O 
Normal EPI and 
NE (sympathetic 
activity) at rest 
and in response to 














Plasma EPI and 
NE (sympathetic 
activity) at rest 





higher in RA 
patients 
 




















ESR 20.3 mm/1st 
hour 







Serum EPI and 
NE (sympathetic 
activity) at rest 






of EPI were 





Basal levels of 
NE were normal 











was normal in RA 
however serum 
NE response was 




















I: Ropes et al 
1958 criteria 
for classical 
or definite RA 
E: None 
reported 





Baseline 24 hour 
urinary adrenaline 









Arterial baroreflex sensitivity  (n=2) 






18 females, 56 
years 
 







24 hour holter 























30 females, 49 
years 
 









rest and in 
response to O 
Reduced arterial 
baroreflex 
sensitivity at rest 




31 females, 43 
years 
 
Pupillary light reflex (n=1) 






18 females, 64 
years (with ocular 
dryness) 
 


























velocity) found in 










33 females, 56 
years 
 
Mean values given unless otherwise indicated.  
ANS = autonomic nervous system, ARA 1987 criteria = American Rheumatism Association 1987 revised 
criteria for the classification of rheumatoid arthritis,(89) BP = blood pressure, BMI = body mass index, CP = 
cold pressor test, CRP = C reactive protein, DAS28 = disease activity score 28, DB = deep breathing, DBP = 
diastolic blood pressure, DC = disease controls, DMARD = disease modifying anti-rheumatic drug, E = 
exclusion, ECG = electrocardiogram, EPI = epinephrine, ESR = erythrocyte sedimentation rate, HC = healthy 
controls, HF = high frequency power in the range 0.15-0.40 Hz, HG = handgrip, HR = heart rate, HRT = 
hormone replacement therapy,  HRV = heart rate variability, I = inclusion, LF = low frequency power in the 
range 0.04-0.15Hz, LF/HF ratio = low frequency to high frequency ratio, N = number of subjects, NE = 
norepinephrine, NN = inter-beat interval, NN50 = number of pairs of adjacent NN intervals differing by more 
than 50 milliseconds in the entire recording, NPY = neuropetide Y, O = orthostasis, pNN50% = NN50 as a 
percentage of the total number of all NN intervals, QIS = quality index score (%), RA = rheumatoid arthritis, RF 
= rheumatoid factor antibody, rMSSD = square root of the mean of the sum of the squares of difference between 
adjacent NN intervals, Ropes et al 1958 criteria = 1958 Revision of diagnostic criteria for rheumatoid 
arthritis,(96) SBP = systolic blood pressure, SD1 = standard deviation of the Poincare plot, SDANN = standard 
deviation of the averages of NN intervals in all 5 minute segments of the entire recording, SDNN = standard 
deviation of all NN intervals, SDSD = standard deviation of differences between adjacent NN intervals, TNF = 













Assessment Key findings QIS 
        
Interventional studies (n=3) 
















disease and not 
received 
remission after 










week 0, 2, 14, 



























Age and BMI 
matched 















16 RA patients. 
 
1 year follow 
up 




















I: ARA 1987 
criteria, fertile 
women were not 
taking 
contraceptives 
and tested in the 
early to mid-





week 0 and 12 
Higher serum 
NPY found 











mm/1st hour cycle 
E: None reported 
inhibitor 
therapy had no 
effect on serum 
NPY levels, 



















in 32 RA 
patients 
 

















E: None reported 










reduced in RA 
patients 
 
























performed in 6 
RA patients 
        
Cohort studies (n=3) 








































































r et al(80) 
2006 RA 
30 





9 swollen joints 
9 tender joints 
63% RF 
positive 












I: ARA 1987 
criteria 





tests (Ziegler et 
al 1992)  
HR variation at 
rest and 
responses to 










60% of RA 
patients 
 
3 of 4 deaths 




had higher HR 
variation 
response to DB, 
but lower HR 
variation to O 
61
% 


































(ESR or IL-6) 
56
% 
        
Other studies (n=1) 




























I: RA (ARA 1987 
criteria) or 
Spondyloarthritis 





















































and tended to 




        
Mean values given unless otherwise indicated.  
ANS = autonomic nervous system, ARA 1987 criteria = American Rheumatism Association 1987 revised 
criteria for the classification of rheumatoid arthritis,(89) BMI = body mass index, CRP = C reactive protein, 
DAS28 = disease activity score 28, DB = deep breathing, DMARD = disease modifying anti-rheumatic drug, E 
= exclusion, ESR = erythrocyte sedimentation rate, HC = healthy controls, HF = high frequency power in the 
range 0.15-0.40 Hz, HR = heart rate, HRT = hormone replacement therapy,  HRV = heart rate variability, I = 
inclusion, IL-6 = interleukin-6, LF = low frequency power in the range 0.04-0.15Hz, LF/HF ratio = low 
frequency to high frequency ratio, N = number of subjects, NN= inter-beat interval, NPY = neuropetide Y, O = 
orthostasis, pNN50% = NN50 as a percentage of the total number of all NN intervals, QIS = quality index score 
(%), RA = rheumatoid arthritis, RF = rheumatoid factor antibody, rMSSD = square root of the mean of the sum 
of the squares of difference between adjacent NN intervals, SBP = systolic blood pressure, SDANN = standard 
deviation of the averages of NN intervals in all 5 minute segments of the entire recording, SDNN = standard 




Table 3. Results Summary: Number of studies with abnormal autonomic function in 
rheumatoid arthritis patients from observational studies 
 Abnormal studies Quality Index Score %; range 
 Number/Total % Normal Abnormal Total 
      
Parasympathetic 20/26 77 65%; 44-78 66%; 33-89 66%; 33-89 
Sympathetic 16/30 53 59%; 28-89 67%; 44-89 63%; 28-89 
Cardiac baroreflex sensitivity 1/2 50 56% 89% 73%; 56-89 
      




Table 4. Results Summary: Outcome of autonomic assessments from case-control studies  
PARASYMPATHETIC RA worse than control No difference RA better than control 
 Number (QIS %; range) Number (QIS %; range) Number (QIS %; range) 
Clinical Cardiovascular 
Tests 
      
Total 11 (63%; 39-89) 2 (61%; 44-78) 0 (NA) 
Heart rate responses to 
deep breathing 
8 5 0 
(51, 62, 74, 75, 77, 79, 
81, 82) 
(53, 58, 76, 78, 83)  
Heart rate responses to 
orthostasis 
7 4 0 
(51, 58, 74, 77-79, 81) (53, 75, 76, 83)  
Heart rate responses to 
Valsalva’s Maneouvre 
5 4 0 
(51, 78, 79, 81, 83) (53, 58, 75, 77)  
Heart rate variability       
Total 8 (70%; 33-89) 5 (71%; 56-89) 0 (NA) 
Frequency domain 5 4* 0 
(55, 59, 61, 68, 77) (51, 86-88)  
Time domain 7 0 0 
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(49, 59, 61, 68, 71, 77, 
88) 
  
Heart rate turbulence 0 1 0 
 (50)  
Respiratory sinus 
arrhythmia 
0 1 0 
 (57)  
Pupillary light reflex       
Total 1 (61%) 0 (NA) 0 (NA) 
Maximum constriction 
velocity 
1 0 0 
(52)   
SYMPATHETIC RA worse than control No difference RA better than control 
 Number (QIS %; range) Number (QIS %; range) Number (QIS %; range) 
Clinical Cardiovascular 
Tests 
      
Total 8 (67%; 44-89) 4 (61%; 44-78) 0 (NA) 
Blood pressure responses 
to orthostasis 
5 4 0 
(51, 54, 74, 77, 81) (53, 75, 76, 79)  
Blood pressure responses 
to hand grip 
4 0 0 
(51, 54, 79, 81)   
Blood pressure responses 
to cold pressor test 
1 0 0 
(54)   
Blood pressure responses 
to mental stress 
2 1 0 
(60, 69) (85)  
Heart rate variability       
Total 3 (80%;72-89) 7 (71%; 61-89) 0 (NA) 
Frequency domain 2 7 0 
 (51, 68) 
 
(55, 59, 61, 77, 86-88)  
Pre-ejection period 1 0 0 
 (57)   
Biomarkers       
Total 3 (61%; 50-67) 2 (44%; 28-61) 0 (NA) 
Neuropeptide-Y 2 2 0 
52 
 
 (64, 72) 
 
(63, 86)  
Chromogranin 1 0 0 
 (56)   
Skin sympathetic 
responses 
      
Total 2 (58%; 50-67) 3 (46%; 39-56) 0 
 (60, 69) (62, 70, 82)  
Catecholamines       
Total 2 (64%; 61-67) 2 (61%; 44-78) 1** (63%) 
Plasma 2 1 1 
 (67, 86) (87) (67)** 
Urinary 0 1 0 
  (66)  
    
BAROREFLEX 
SENSITIVITY 
RA worse than control No difference RA better than control 
Number (QIS %; range) Number (QIS %; range) Number (QIS %; range) 
Cardiac baroreflex 
sensitivity 
      
Total 1 (89%) 1 (56%) 0 (NA) 
Spontaneous 1 0 0 
 (51)   
Heart rate turbulence 0 1 0 
  (50)  
QIS = quality index score, RA = rheumatoid arthritis. 
* This study (88) is included in two categories as the authors reported abnormal time domain heart rate 
variability parameters (worse than control) but normal frequency domain (no difference). 
** This study (67) is included in two categories as the authors reported lower resting sympathetic activity (better 




Table 5. Results Summary: Outcome of associations between autonomic function and 
inflammation in RA  
 Outcome 
 Association found No association 
   
Clinical cardiovascular tests (n=9) 2 (42%; 39-44) 7 (73%; 56-89) 
Heart rate variability (n=5) 3 (77%; 72-88) 2 (72%; 56-89) 
Catecholamines (n=2)  2 (67%; 56-78) 
Biomarkers (n=2) 1 (67%) 1 (67%) 
Pupillary light reflex (n=1) 1 (61%)  
   
TOTAL 7 (64%; 39-88) 12 (71%; 56-89) 
 




FIGURE LEGENDS  
 
Figure 1. Simplified schematic showing autonomic regulation of the cardiovascular system 
and the effects of pro-inflammatory cytokines from experimental studies 
 
A Nerve signals from the brain stem are relayed to various organs in the autonomic nervous 
system. Parasympathetic activation results in slowing of the heart rate, whereas sympathetic 
activation causes increased ventricular contraction, peripheral and renal vasoconstriction, 
activation of the renin-angiotensin-aldosterone system, increased sodium retention (kidneys), 
epinephrine and norepinephrine release (adrenal glands) and increased inflammation 
(leukocyte activation and increased cytokine production in the spleen). Central and peripheral 
feedback mechanisms are in place (e.g. arterial and cardiopulmonary baroreceptors, 
chemoreceptors) to ensure homeostasis is maintained. B Experimental studies have shown 
that pro-inflammatory cytokines (e.g. interleukin 1-Beta, interleukin 6 and tumour necrosis 
factor alpha) attenuate (-) cardiovagal baroreflex sensitivity and heart rate variability, as well 
as heighten (+) sympathetic activity.  
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Appendix 1. Quality index score (QIS) assessment tool criteria 
Index Criteria Assessed 
 High = 2 points Medium = 1 point Low = 0 points 
    
1. Study Design Case-control study 
with appropriate 
matching (e.g. age, sex, 
body mass index); 
and/or interventional 
with assessment before 
and after biologic agent
Case-control study but 
inappropriately 
matched 




no control group 
 
Rationale A case-control study with appropriate matching is the best study 
design to answer the principle question of the study – is autonomic 
dysfunction present in rheumatoid arthritis? 
An interventional study with assessment before and after biologic 
agent is the best study design to answer another principle question – 
is there a link between inflammation and autonomic function in RA?




Patients included with 
a formal rheumatoid 
arthritis diagnosis 
according to 
recognised criteria and 
those with conditions 
Patients included with 
a formal rheumatoid 
arthritis diagnosis 
according to 
recognised criteria but 












or medications that 
interfere with 
autonomic function not 
excluded 
Rationale In order to establish meaningful conclusions from the study  patients 
included must have the correct diagnosis according to recognised 
criteria and to prevent confounding factors those with condition or 
medications affecting autonomic function should be excluded 
    
3. Disease 
characteristics 
Mentioned in detail 
(i.e. at least 2): disease 
duration, inflammatory 
marker e.g. C-reactive 
protein or erythrocyte 
sedimentation rate, 
swollen or tender 
joints, medications, 
functional capacity 
Mentioned only 1: 
disease duration, 
inflammatory marker 
e.g. C-reactive protein 
or erythrocyte 
sedimentation, swollen 





Rationale Disease characteristics are necessary to determine the inflammatory 
status of the rheumatoid arthritis patients tested at the time of the 
study. They allow for meaningful interpretation and comparison 
between different studies. 
    
4. Standardised 
testing condition 
Mentioned in detail 
(i.e. at least 2): e.g. 
Mentioned only 1: e.g. 






temperature, time of 
testing, fasting status, 
subject position 
temperature, time of 
testing, fasting status, 
subject position 
standardised 
Rationale Testing conditions can affect the results of autonomic function 
assessments and hence unwanted bias can be avoided by 
standardising the testing conditions for each subject. 





Mentioned that the 
study adhered to 




Mentioned that the 
study adhered to 
published guidelines 
and protocols but 
important details 
missing; or mentioned 
that study was adapted 
from guidelines or 
protocols 
No mention of 
guidelines or 
protocols 
Rationale Adhering to published guidelines or protocols ensures that testing is 
performed to the highest standard available and allows for 
meaningful comparison between different studies. 
  
6. Autonomic 
assessment – quality 
of test 
Autonomic function 
assessed using a 
recognised and 
validated tool, and a 
Autonomic function 
assessed using a 
recognised tool but a 
basic assessment 
Unrecognised 
tool to measure 
autonomic 





(i.e. more than one 
technique employed) 
 
Gold standard or close 
to gold standard 
assessment of 
autonomic function 




of autonomic function 








Rationale A comprehensive assessment of autonomic function involves using 
the best validated tools with numerous aspects of autonomic 
function tested 
  




performed to determine 
sample size and sample 
size achieved 
Power calculation 
performed to determine 
sample size but sample 
size not achieved 
No mention of 
power 
calculation 
Rationale In order to prevent type 2 errors the correct sample size should be 
calculated in advance and reached. 
  




test applied and 
comprehensive details 
mentioned with 
adjustment made for 
Appropriate statistical 
test applied but lacking 
details with no 














Rationale Choosing the most appropriate statistical test ensures accurate 
results and adjusting for co-variables helps to minimise the bias, 







(e.g. using regression 
analysis) and 







(e.g. using regression 
analysis) but no 








Rationale To determine whether links between inflammation and autonomic 
function in RA exist associations between indices of inflammation 
and parameters of autonomic function need to be made. 
    
Each index was graded between 0-2, and the total points added to give a final score between 
0-18. If an index was found to be inappropriate (or irrelevant) to a particular study then the 
index was omitted and the total score reduced to 16. This occurred in studies employing 24 
hour home assessments (e.g. 24 hour electrocardiogram monitor or urinary testing) where the 
index “standardised test conditions” did not apply. For all studies a percentage was calculated 
66 
 
to give a Quality Index Score (QIS). The quality assessment was performed by two 






Appendix 2. Prevalence of autonomic nervous system dysfunction in rheumatoid arthritis 
 




    
Aydemir et al 
2010 
36 Ewing test.(28) Two of five abnormal tests from:  
 
Heart rate response to Valsalva’s manoeuvre 
(Valsalva ratio≤1.1) 
Heart rate variation during deep breathing (inter-
beat interval maximum-minimum ≤10) 
Heart rate response to standing (30:15 ratio≤1.0)  
Blood pressure response to standing (fall in systolic 
blood pressure≥20) 
Blood pressure response to handgrip (diastolic 
blood pressure rise ≤10mmHg) 
61 
  Modified (by authors) Ewing test.(51) Two 
abnormal and one borderline from:  
 
Ewing test + inspiration/expiration heart rate ratio 
≤1 
Blood pressure response to orthostasis (fall in 
diastolic blood pressure≥10mmHg)  
75 
    
Bidikar et al 2010 50 Fall in systolic blood pressure in response to 
orthostasis ≥10mmHg 
44 
    
Milovanovic et al 
2010 
50 Two of three positive tests from:  
 
Blood pressure response to orthostasis 
Heart rate response to deep breathing 
Heart rate response to orthostasis
86 
    
Stojanovic  al 
2007 





Blood pressure response to orthostasis 
Blood pressure response to handgrip 
Heart rate response to deep breathing 
Heart rate response to orthostasis 
Heart rate response to Valsava’s manoeuvre 
Moderate to severe autonomic nervous system 
(ANS) dysfunction: Ewing score≥4 
    
Schwemmer et al 
2006 
30 Ewing test (result below 5th percentile) 43 
  Two of five abnormal (below 5th centile from 
normal healthy control subjects) tests from:  
RRI variation at rest 
RRI variation  difference between deep breathing 
and rest 
RRI variation  difference between deep breathing 
and rest 
Valsalva’s manoeuvre (RRI maximum/RRI 
minimum) 
Heart rate response to orthostasis, blood pressure 
fall ≥25mmHg 
20 
  One of two abnormal (below 5th centile from normal 
healthy control subjects) tests from:  
 
Latency time of pupillary reflex 
Maximal pupillary area 
50 
  Cardiovascular and pupillary dysfunction (both of 
the above abnormal) 
60 
    
Gozke et al 2003 10 Inter-beat interval (RRI) variation difference 
between DB and rest 
50 
  RRI variation ratio of deep breathing to rest 80 
    
Geenen et al 1996 13 Lower mean response to cognitive discrimination 
than the least responding control 
38 
    
Tousirrot et al 
1993 
50 Two of three abnormal tests from:  
Heart rate response to deep breathing 
Heart rate response to orthostasis 
Heart rate response to Valsalva’s manoeuvre 
60 
    
Edmonds et al 
1979 
27 Heart rate response to orthostasis, RRI ratio<1 33 
 
N = number of rheumatoid arthritis patients. Prevalence (%) values given are means either 
quoted or calculated from the study. 
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Fig 1 
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Fig 2 
 
 
 
